Eli Lilly and Co. entered an exclusive global licensing and research collaboration with Sitryx, a biopharma company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four preclinical targets identified by Sitryx that could lead to potential new medicines for autoimmune diseases. Sitryx will receive $50 million upfront and Lilly will make a $10 million equity investment in Sitryx. Sitry...